Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells

Leukemia

Volumn 17, Issue 2, 2003, Pages 350-358

  Klisovic, M I ^a   Maghraby, E A ^a   Parthun, M R ^a   Guimond, M ^a   Sklenar, A R ^a   Whitman, S P ^a   Chan, K K ^a   Murphy, T ^c   Anon, J ^a   Archer, K J ^a   Rush, L J ^b   Plass, C ^a   Grever, M R ^a   Byrd, J C ^a   Marcucci, G ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

5 aza 2 deoxycytidine; Acute myeloid luekemia; AML1 ETO; Depsipeptide; Histone deacetylase

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CD11B ANTIGEN; DEPSIPEPTIDE; DNA METHYLTRANSFERASE; FR 901228; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; HYBRID PROTEIN; INTERLEUKIN 3; METHYLTRANSFERASE INHIBITOR; PHOSPHOPROTEIN;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG TARGETING; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSCRIPTION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LEUKEMOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION;

EID: 0037328501     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402776     Document Type: Article

References (32)

1. Redner RL, Wang J, Liu JM. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 1999; 94: 417-428.
2. Blobel GA. CREB-binding protein and p300: molecular integrators of hematopoietic transcription. Blood 2000; 95: 745-755.
3. Marcucci G, Caligiuri MA, Bloomfield CD. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. Cancer Invest 2000; 18: 768-780.
4. Lutterbach B, Hiebert SW. Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation. Gene 2000; 245: 223-235.
5. Speck NA, Stacy T, Wang Q, North T, Gu TL, Miller J, Binder M, Marin-Padilla M. Core-binding factor: a central player in hematopoiesis and leukemia. Cancer Res 1999; 59: 1789s-1793s.
6. Uchida H, Zhang J, Nimer SD. AML1A and AML1B can transactivate the human IL-3 promoter. J Immunol 1997; 158: 2251-2258.
7. Erickson PF, Dessev G, Lasher RS, Philips G, Robinson M, Drabkin HA. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease. Blood 1996; 88: 1813-1823.
8. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA 1998; 95: 10860-10865.
9. Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR, Huynh KD, Bardwell VJ, Lavinsky RM, Rosenfeld MG, Glass C, Seto E, Hiebert SW. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 1998; 18: 7176-7184.
10. Gelmett V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 1998; 18: 7185-7191.
11. Pandolfi PP. Histone deacetylases and transcriptional therapy with their inhibitors. Chemother Pharmacol Cancer 2001; 48: S17-S19.
12. Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, Shimomura K. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo) 1994; 47: 315-323.
13. Ueda H, Nakajima H, Hori Y, Goto T, Okuhara M. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci Biotechnol Biochem 1994; 58: 1579-1583.
14. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 1998; 241: 126-133.
15. Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW, Dawson NA, Grever MR. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells [published erratum appears in Blood 2000 Jan 15;95(2):409]. Blood 1999; 94: 1401-1408.
16. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8: 718-728.
17. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, Kingma DM, Turner ML, Altemus R, Bates SE. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001; 98: 2865-2868.
18. Bruner RJ, Marcucci G, Binkley P, Fischer B, Parthun M, Davis M, Xiao J, Chan K, Wright J, Grever MR, Byrd JC. A phase I study to determine minimally effective pharmacologic dose (MEPF) of depsipeptide (FR901228) in selected hematologic malignancies. Proc Am Soc Clin Oncol 2002; 21: 265A.
19. Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 1991; 77: 2031-2036.
20. Parthun MR, Widom J, Gottschling DE. The major cytoplasmic histone acetyltransferase in yeast: links to chromatin replication and histone metabolism. Cell 1996; 87: 85-94.
21. Marcucci G, Caligiuri MA, Dohner H, Archer KJ, Schlenk RF, Dohner K, Maghraby EA, Bloomfield CD. Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. Leukemia 2001; 15: 1072-1080.
22. Lai CK, Ho SS, Chan CH, Leung R, Lai KN. Gene expression of interleukin-3 and granulocyte macrophage colony-stimulating factor in circulating CD4+ T cells in acute severe asthma. Clin Exp Allergy 1996; 26: 138-146.
23. Marcucci G, Strout, MP, Bloomfield CD, Caligiuri MA. Detection of unique ALL1 (MLL) fusion transcripts in normal human bone marrow and blood: distinct origin of normal versus leukemic ALL1 fusion transcripts. Cancer Res 1998; 58: 790-793.
24. Bestor TH. Gene silencing. Methylation meets acetylation. Nature 1998; 393: 311-312.
25. Ng HH, Bird A. DNA methylation and chromatin modification. Curr Opin Genet Dev 1999; 9: 158-163.
26. Wang J, Saunthararajah Y, Redner RL, Liu JM. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res 1999; 59: 2766-2669.
27. Ferrara FF, Fazi F, Bianchini A, Padula F, Gelmetti V, Minucci S, Mancini M, Pelicci PG, Lo Coco F, Nervi C. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 2001; 61: 2-7.
28. Turner BM. Histone acetylation and an epigenetic code. Bioessays 2000; 22: 836-845.
29. Akhtar A, Becker P. Activation of transcription through histone H4 acetylation by MOF, an acetyltransferase essential for dosage compensation in Drosophila. Mol Cell 2000; 5: 367-375.
30. Smith E, Pannuti A, Gu W, Steurnagel A, Cook R, Allis C, Lucchesi J. The drosophila MSL complex acetylates histone H4 at lysine 16, a chromatin modification linked to dosage compensation. Mol Cell Biol 2000; 20: 312-318.
31. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, Fuks F, Lo Coco F, Kouzarides T, Nervi C, Minucci S, Pelicci PG. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002; 295: 1079-1082.
32. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103-107.